Latest news with #Kaye
Metro
a day ago
- Entertainment
- Metro
Veteran rocker, 90, shockingly turns down Rock and Roll Hall of Fame induction
In a surprising move, legendary bassist and session musician Carol Kaye, aged 90, has declined to participate in her 2025 induction into the Rock and Roll Hall of Fame. She claims the honour fails to reflect the collective spirit and behind-the-scenes artistry of the studio musicians who helped shape the sound of modern music. Kaye, whose staggering career includes an estimated 10,000 recording sessions with artists like The Beach Boys, Simon & Garfunkel, and Frank Zappa, was selected this year in the Musical Excellence category. But in a candid Facebook post earlier this week, she announced she won't be attending the ceremony or accepting the accolade. 'NO I won't be there,' Kaye wrote. 'I am declining the RRHOF awards show … turning it down because it wasn't something that reflects the work that studio musicians do and did in the golden era of the 1960s recording hits.' Kaye's decision is distinctly political, a pointed critique of an industry that has long celebrated frontmen and solo acts while often ignoring the unsung people behind the curtain. In her post, Kaye emphasised that the era's music was made by a massive, collaborative effort, hundreds of skilled musicians working as a tight unit in Hollywood's studio scene. 'You are always part of a TEAM, not a solo artist at all,' she wrote. \There were always 350–400 studio musicians (AFM Local 47 Hollywood) working in the busy 1960s… Since 1930s, I was never a 'wrecker' at all — that's a terrible insulting name.' The 'wrecker' reference touches on another sore point for Kaye. She has long bristled at the posthumous branding of her peers as The Wrecking Crew, which was a label popularized by drummer Hal Blaine and later immortalized in a 2008 documentary directed by Denny Tedesco, which Kaye has also distanced herself from. Kaye's path to icon status was unconventional. A self-described jazz guitarist in the 1950s, she was roped into session work by Bumps Blackwell in 1957 and fell into bass playing by accident in 1963 when a scheduled player didn't show up. 'I never played bass in my life' she wrote. 'But being an experienced recording guitarist, it was plain to see that three bass players hired to play 'dum-de-dum' on record dates wasn't getting it. It was easy for me to invent good bass lines.' More Trending That spontaneous switch marked the beginning of one of the most prolific and creative bass careers in popular music. Her Facebook post closed with a graceful but firm rejection of what she sees as a flawed system of recognition. 'I refuse to be part of a process that is something else rather than what I believe in, for others' benefit and not reflecting on the truth,' she wrote. 'We all enjoyed working with EACH OTHER. Thank you for understanding.' Got a story? If you've got a celebrity story, video or pictures get in touch with the entertainment team by emailing us celebtips@ calling 020 3615 2145 or by visiting our Submit Stuff page – we'd love to hear from you. MORE: Fans are all saying the same thing after Tom Cruise finally gets his Oscar MORE: R Kelly begged for Trump's help before 'murder plot' that saw him overdose in prison MORE: TV chef Anne Burrell's suspected cause of death aged 55 revealed
USA Today
a day ago
- Entertainment
- USA Today
Carol Kaye is 'declining' her invitation to the 2025 Rock and Roll Hall of Fame induction ceremony
Carol Kaye is 'declining' her invitation to the 2025 Rock and Roll Hall of Fame induction ceremony Show Caption Hide Caption 2025 Rock & Roll Hall of Fame inductees announced The Rock & Roll Hall of Fame has announced its 2025 inductees, which include hip-hop pioneers Outkast and '80s icon Cyndi Lauper. unbranded - Entertainment Carol Kaye, one of the most recorded bassists in rock and pop music, announced on June 18 that she will be declining her invitation to this year's Rock & Roll Hall of Fame induction ceremony. 'People have been asking: NO I won't be there,' wrote the 90-year-old musician in a since-deleted Facebook post. 'I am declining the RRHOF awards show (and Denny Tedesco process)... because it wasn't something that reflects the work that Studio Musicians do and did in the golden era of the 1960s Recording Hits.' During the 1960s and 1970s, Kaye was part of a group of session musicians in Los Angeles known as the Wrecking Crew, a collective which often collaborated with the Beach Boys, Phil Spector, the Monkees and more. In 2008, Denny Tedesco directed a documentary on the group, which featured Kaye. However, the 90-year-old musician has long objected to the group moniker. In a 2015 interview, Kaye said the 'first time that phrase was used' was in Hal Blaine's book. 'I had no idea he was going to do something phoney… It's a lie. We were all independent people, there was no set band,' she said. Hal Blaime, a 'Wrecking Crew' drummer, said in the same interview that Kaye had 'somehow forgotten' that 'The Wrecking Crew was established in the early 1960s.' 'I was never a 'wrecker' at all,' she wrote in her recent Facebook post. 'That's a terrible insulting name.' Kaye ended her post with a strong dissent, 'I refuse to be part of a process that is something else rather than what I believe in, for others' benefit and not reflecting on the truth – we all enjoyed working with EACH OTHER.' Kaye will still be inducted into the Rock & Roll Hall of Fame despite her absence at the 2025 induction ceremony, where she was set to recieve the Musical Excellence Award. Other inductees this year include Bad Company, Joe Cocker, Chubby Checker, Cyndi Lauper, OutKast, Soundgarden, and The White Stripes. The complete list: 2025 Rock and Roll Hall of Fame inductees
Daily Mirror
a day ago
- Health
- Daily Mirror
Kaye Adams taken aback by co-star's 'remarkable' reaction to cancer news
Loose Women star Kaye Adams has been left stunned by her friend Karen MacKenzie's reaction to being diagnosed with breast cancer Kaye Adams of Loose Women has shared her utter astonishment at how her friend coped with a breast cancer diagnosis. Her friend and podcast co-star Karen MacKenzie, discovered an unsettling lump in her breast and immediately sought medical advice. On their How To Be 60 podcast, Karen detailed the swift action taken by the NHS: "That day, I got a mammogram. I got an ultrasound, and I got a biopsy. By the end of the appointment, it was quite clear that there was a cancerous tumour there." But rather than allowing the news to derail her plans, Karen jetted off to Italy for a break before further examination. Upon her return, she underwent an MRI that revealed additional tumours—the initial lump being benign and the opposing breast harbouring the malignant growths. Reflecting on her condition, Karen admitted to overlooking subtle signs: "Now that I see my breasts though, there was a tiny little sort of ripple at the bottom. And I think that's all I could describe it just a little bit of a tuck in the skin, and that's an indication." Despite the intensive treatment and more procedures on the horizon, Karen has maintained a lighthearted and pragmatic stance towards her illness. This strength and resilience have left Kaye incredibly impressed, saying on the podcast: "I have to say, you're handling this incredibly, I really do take my hat off to you. I think you've been remarkable in terms of the way you're dealing with it." Kaye highlighted Karen's remarkable resilience, noting that she even cycled to some of her appointments, showcasing her stoic approach to her condition. Karen recalled discovering lumps in her breast previously — once during breastfeeding and again after being prescribed HRT during menopause — though neither proved to be cancerous. She speculated: "I have no reason to believe this, but in the back of my mind, I think the benign lump here was maybe brought on by HRT. I don't know that, because I stopped HRT as soon as I realised." Medical professionals acknowledge that while there is no concrete evidence directly linking HRT to cancer, it can marginally elevate the risk of certain types, particularly breast cancer, as well as possibly ovarian or womb cancer. The risk is influenced by the type of HRT, treatment duration, and personal factors such as age and family history. Karen confessed she had the occasional "wobble," saying: "I think it was hard," yet she believes she might still be partly in denial about her condition. She expressed her uncertainty: "I don't know whether my head's still in the sand," adding, "I'm not in any pain. I wouldn't think there's anything wrong with me. I don't feel any lumps on that side. It's just like it's happening to somebody else." Kaye has been deeply impressed by her friend's philosophical stance towards the unexpected diagnosis. Meanwhile, Cancer Research UK suggests that maintaining a positive outlook can significantly aid those grappling with the daunting reality of cancer.
Yahoo
2 days ago
- Business
- Yahoo
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen's Board of Directors and Chair of the Science Committee since 2020, brings highly relevant and extensive experience in central nervous system (CNS) therapeutic development, regulatory strategy, and medical affairs to the NervGen team. The expanded engagement follows the company's announcement of positive topline results in the chronic cohort of the Phase 1b/2a clinical trial evaluating NVG-291 in individuals with cervical spinal cord injury. "We are very pleased to welcome Dr. Kaye in his expanded capacity as a medical advisor to the company," said Mike Kelly, NervGen's President & CEO. "In addition to his close history and contributions to the NVG-291 program, he brings extensive industry and CNS development expertise focused on clinical and regulatory strategy. Dr. Kaye has highly relevant experience and is well positioned to assist the team in analyzing the complete chronic cohort data and help chart the next phase of NVG-291's clinical and regulatory pathway, which includes assisting in preparations for our anticipated meeting with the U.S. Food and Drug Administration (FDA) in the second half of this year." As a NervGen Board member and Science Committee Chair, Dr. Kaye has served as an advisor to the NVG-291 program since its early clinical development. He previously served as chief medical officer of multiple biopharmaceutical companies, including most recently at Longboard Pharmaceuticals Inc., where he helped guide CNS development programs through a $2.6 billion acquisition by H. Lundbeck A/S. His expertise spans the areas of neurology, psychiatry, immunology, and infectious disease, and includes oversight of clinical operations, regulatory affairs, and medical strategy. Dr. Kaye earned his MD, MPH, and BS degrees from George Washington University and completed a Research Fellowship at Harvard Medical School. About NVG-291 NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. These studies implicated several potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA for NVG-291 in individuals with spinal cord injury. About NervGen NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated promising changes in a secondary endpoint assessing hand function. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. Contacts Huitt Tracey, Investor Relationshtracey@ Bill Adams, Chief Financial Officerinfo@ Christy CurranSam Brown Healthcare Communicationschristycurran@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the strategic guidance to be provided by the chief medical advisor; the anticipated meeting with the FDA; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the future development plans and benefits of NVG-291; the development plans and prospective target indications for NVG-300; and the creation of neuroreparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Boston Globe
12-06-2025
- General
- Boston Globe
The reverence for Old Glory that inspired Flag Day arose decades after Betsy Ross sewed her first
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Americans' attachment to their flag is imbued with feelings that in other nations might attach to a beloved monarch or an official national religion. The flag is a physical object 'that people can relate to,' said Charles Spain, director of the Flag Research Center in Houston. Advertisement 'If you put a flag on a pole, the wind makes it move,' Spain, a retired Texas Court of Appeals justice, added. 'Therefore, the flag is alive.' What does Flag Day celebrate? The holiday marks the date in 1777 that the Continental Congress approved the design of a national flag for what to Great Britain were rebellious American colonies. It set the now-familiar 13 alternating horizontal stripes of red and white, one for each self-declared US state, along with the blue upper quadrant with white stars. The Journals of Congress from 1777 says that the stars represented 'a new constellation,' but a 1818 law mandated one white star for each state. Advertisement National observances for Flag Day began well ahead of the law signed by Truman, with a proclamation issued by President Woodrow Wilson in 1916. Wilson's action came several decades after communities began Flag Day celebrations. In 1891, Philadelphia held its first — at one of Ross' former homes — and it evolved into an annual, weeklong Flag Fest. The small village of Waubeka, Wisconsin, north of Milwaukee, claims the first observance in 1885. According to the National Flag Day Foundation headquartered there, a 19-year-old teacher in a one-room school, Bernard Cigrand, put a small flag on his desk and had students write essays about what the flag meant to them. He advocated a national holiday for decades as he worked as a dentist in the Chicago area. When did the US flag become sacred to many Americans? Lisa Acker Moulder, director of the Betsy Ross House historical site in Philadelphia, said that for Ross, conferring with Washington would have been the key point of her account. The US flag wasn't as venerated before the Civil War in 1861-65 as it is now. Keeping flags aloft was crucial to maneuvering troops in Civil War battles, and that made flag bearers big targets for the enemy. They couldn't shoot back and had to stand tall, said Ted Kaye, secretary for the North American association for flag scholars, known as vexillologists. Both sides' propaganda told soldiers that carrying a flag into battle was an honor reserved for the most morally fit — and that view took hold, Kaye said. One Michigan cavalry regiment's red flag declared, 'Fear Not Death --Fear Dishonor.' Advertisement 'This created this cult of honor around these battle flags, and around, by extension, the national flag,' Kaye said. Why was the Civil War so important? Civil War soldiers showed extraordinary courage under fire to keep their colors aloft, and multiple flag bearers died in single battles, said Matt VanAcker, who directs a now decades-old project at the Michigan Capitol to conserve flags from the Civil War and later conflicts. Michigan has collected about 240 old battle flags and had a display in its Capitol rotunda for decades. Replicas have replaced them so that the original banners — and pieces of banners — can be preserved as a physical link to the soldiers who fought under them. 'Many of the flags in our collection are covered with bullet holes,' VanAcker said. 'A lot of them have blood stains — the physical evidence of their use on the battlefield.'
